Clinical Trial Update: A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. [Phase 1]

View source ↗

Summary

This Phase 1 trial of FAZ053 as a single agent and in combination with PDR001 in patients with advanced malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alveolar Soft Part Sarcoma
• Chordoma
• Triple-negative Breast Cancer

Drugs mentioned

• FAZ053
• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Solid Tumors, Triple Negative Breast Cancer | Phase 1 | Status: TERMINATED